Eyepoint Pharmaceuticals, Inc. (EYPT) SEC Filings — 2025
21 SEC filings for Eyepoint Pharmaceuticals, Inc. (EYPT) in 2025.
Filings
- EyePoint Pharmaceuticals Files 8-K — 8-K · Dec 8, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · Nov 19, 2025
- EyePoint's R&D Soars, Net Loss Widens Amid DURAVYU Trials — 10-Q · Nov 6, 2025
- EyePoint Pharmaceuticals Files 8-K on Financials — 8-K · Nov 5, 2025
- EyePoint Pharmaceuticals Enters Material Definitive Agreement — 8-K · Oct 17, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · Oct 14, 2025
- EyePoint's Q2 Loss Widens on Soaring R&D for Key Drug — 10-Q · Aug 7, 2025
- EyePoint Pharmaceuticals Files 8-K on Financials — 8-K · Aug 6, 2025
- EyePoint Pharmaceuticals Files 8-K/A Amendment — 8-K/A · Jul 29, 2025
- EyePoint Pharmaceuticals Announces Executive and Board Changes — 8-K · Jun 20, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · May 27, 2025
- EyePoint Pharma Files Proxy Statement Amendment — DEFA14A · May 9, 2025
- EyePoint Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 8, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · May 7, 2025
- EyePoint Pharma Files DEF 14A for Executive Compensation — DEF 14A · Apr 28, 2025
- EyePoint Pharma Files 2024 10-K — 10-K · Mar 6, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · Mar 5, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · Mar 4, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · Feb 5, 2025
- EyePoint Pharmaceuticals Files 8-K — 8-K · Jan 13, 2025
- EyePoint Pharma Shuffles Execs and Board — 8-K · Jan 8, 2025